Merck KGaA confirms late-stage talks with SpringWorks about $3.5B buyout
Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. The German drugmaker confirmed it is in late-stage talks about buying the rare cancer biotech for around $47 a share.
Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. The German drugmaker confirmed it is in late-stage talks about buying the rare cancer biotech for around $47 a share.
